Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
14
LEXX Quote, Financials, Valuation and Earnings
Last price:
$0.62
Seasonality move
:
28.99%
Day range:
$0.64 - $0.70
52-week range:
$0.46 - $1.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
23.44x
P/B ratio:
3.23x
Volume:
150.1K
Avg. volume:
255K
1-year change:
-60.4%
Market cap:
$15.9M
Revenue:
$705.9K
EPS (TTM):
-$0.57
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LEXX
Lexaria Bioscience Corp.
|
$100K | -- | -42.53% | -- | $4.50 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$74.7M | $0.22 | 20.79% | 10.43% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.12 | -- | -68.5% | $10.30 |
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -- | -- | -- | $64.52 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.20 | -100% | -36.92% | $55.82 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LEXX
Lexaria Bioscience Corp.
|
$0.64 | $4.50 | $15.9M | -- | $0.00 | 0% | 23.44x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$14.38 | $16.67 | $1.9B | 25.63x | $0.00 | 0% | 7.63x |
|
EDSA
Edesa Biotech, Inc.
|
$1.07 | $11.00 | $7.5M | -- | $0.00 | 0% | 31.22x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.85 | $10.30 | $91.8M | -- | $0.00 | 0% | -- |
|
PMN
ProMIS Neurosciences, Inc.
|
$14.61 | $64.52 | $31.4M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$42.76 | $55.82 | $3.3B | -- | $0.00 | 0% | 449.37x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LEXX
Lexaria Bioscience Corp.
|
2.03% | -0.383 | 0.43% | 3.04x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | 0.004 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -1.338 | -- | 10.60x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.996 | 0.41% | 1.61x |
|
PMN
ProMIS Neurosciences, Inc.
|
-- | 0.176 | -- | 1.26x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | -0.106 | 0.27% | 12.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LEXX
Lexaria Bioscience Corp.
|
-$24.2K | -$1.6M | -186.06% | -189.86% | -2155.4% | -$989.2K |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.9K | -$2.5M | -77.45% | -77.48% | -- | -$1.8M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -$11.8M | -348.3% | -348.3% | -- | -$10.2M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
Lexaria Bioscience Corp. vs. Competitors
-
Which has Higher Returns LEXX or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -2178.51% compared to Lexaria Bioscience Corp.'s net margin of 42.95%. Lexaria Bioscience Corp.'s return on equity of -189.86% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital LEXXLexaria Bioscience Corp.91.15% -$0.07 $4.6M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About LEXX or AUPH?
Lexaria Bioscience Corp. has a consensus price target of $4.50, signalling upside risk potential of 605.77%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 14.86%. Given that Lexaria Bioscience Corp. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LEXXLexaria Bioscience Corp.1 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is LEXX or AUPH More Risky?
Lexaria Bioscience Corp. has a beta of 0.562, which suggesting that the stock is 43.753% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.504, suggesting its more volatile than the S&P 500 by 50.415%.
-
Which is a Better Dividend Stock LEXX or AUPH?
Lexaria Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience Corp. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEXX or AUPH?
Lexaria Bioscience Corp. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Lexaria Bioscience Corp.'s net income of -$1.6M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Lexaria Bioscience Corp.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 25.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience Corp. is 23.44x versus 7.63x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEXXLexaria Bioscience Corp.23.44x -- -- -$1.6M AUPHAurinia Pharmaceuticals, Inc.7.63x 25.63x $73.5M $31.6M
-
Which has Higher Returns LEXX or EDSA?
Edesa Biotech, Inc. has a net margin of -2178.51% compared to Lexaria Bioscience Corp.'s net margin of --. Lexaria Bioscience Corp.'s return on equity of -189.86% beat Edesa Biotech, Inc.'s return on equity of -77.48%.
Company Gross Margin Earnings Per Share Invested Capital LEXXLexaria Bioscience Corp.91.15% -$0.07 $4.6M EDSAEdesa Biotech, Inc.-- -$0.32 $12.5M -
What do Analysts Say About LEXX or EDSA?
Lexaria Bioscience Corp. has a consensus price target of $4.50, signalling upside risk potential of 605.77%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 928.04%. Given that Edesa Biotech, Inc. has higher upside potential than Lexaria Bioscience Corp., analysts believe Edesa Biotech, Inc. is more attractive than Lexaria Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings LEXXLexaria Bioscience Corp.1 0 0 EDSAEdesa Biotech, Inc.2 0 0 -
Is LEXX or EDSA More Risky?
Lexaria Bioscience Corp. has a beta of 0.562, which suggesting that the stock is 43.753% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.208, suggesting its less volatile than the S&P 500 by 79.169%.
-
Which is a Better Dividend Stock LEXX or EDSA?
Lexaria Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience Corp. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEXX or EDSA?
Lexaria Bioscience Corp. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Lexaria Bioscience Corp.'s net income of -$1.6M is higher than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Lexaria Bioscience Corp.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience Corp. is 23.44x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEXXLexaria Bioscience Corp.23.44x -- -- -$1.6M EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M
-
Which has Higher Returns LEXX or ONCY?
Oncolytics Biotech, Inc. has a net margin of -2178.51% compared to Lexaria Bioscience Corp.'s net margin of --. Lexaria Bioscience Corp.'s return on equity of -189.86% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital LEXXLexaria Bioscience Corp.91.15% -$0.07 $4.6M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About LEXX or ONCY?
Lexaria Bioscience Corp. has a consensus price target of $4.50, signalling upside risk potential of 605.77%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $10.30 which suggests that it could grow by 1107.32%. Given that Oncolytics Biotech, Inc. has higher upside potential than Lexaria Bioscience Corp., analysts believe Oncolytics Biotech, Inc. is more attractive than Lexaria Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings LEXXLexaria Bioscience Corp.1 0 0 ONCYOncolytics Biotech, Inc.4 1 0 -
Is LEXX or ONCY More Risky?
Lexaria Bioscience Corp. has a beta of 0.562, which suggesting that the stock is 43.753% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.988, suggesting its less volatile than the S&P 500 by 1.202%.
-
Which is a Better Dividend Stock LEXX or ONCY?
Lexaria Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience Corp. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEXX or ONCY?
Lexaria Bioscience Corp. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Lexaria Bioscience Corp.'s net income of -$1.6M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Lexaria Bioscience Corp.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience Corp. is 23.44x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEXXLexaria Bioscience Corp.23.44x -- -- -$1.6M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns LEXX or PMN?
ProMIS Neurosciences, Inc. has a net margin of -2178.51% compared to Lexaria Bioscience Corp.'s net margin of --. Lexaria Bioscience Corp.'s return on equity of -189.86% beat ProMIS Neurosciences, Inc.'s return on equity of -348.3%.
Company Gross Margin Earnings Per Share Invested Capital LEXXLexaria Bioscience Corp.91.15% -$0.07 $4.6M PMNProMIS Neurosciences, Inc.-- -$5.93 $9.2M -
What do Analysts Say About LEXX or PMN?
Lexaria Bioscience Corp. has a consensus price target of $4.50, signalling upside risk potential of 605.77%. On the other hand ProMIS Neurosciences, Inc. has an analysts' consensus of $64.52 which suggests that it could grow by 341.6%. Given that Lexaria Bioscience Corp. has higher upside potential than ProMIS Neurosciences, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than ProMIS Neurosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LEXXLexaria Bioscience Corp.1 0 0 PMNProMIS Neurosciences, Inc.2 0 0 -
Is LEXX or PMN More Risky?
Lexaria Bioscience Corp. has a beta of 0.562, which suggesting that the stock is 43.753% less volatile than S&P 500. In comparison ProMIS Neurosciences, Inc. has a beta of -0.074, suggesting its less volatile than the S&P 500 by 107.419%.
-
Which is a Better Dividend Stock LEXX or PMN?
Lexaria Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProMIS Neurosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience Corp. pays -- of its earnings as a dividend. ProMIS Neurosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEXX or PMN?
Lexaria Bioscience Corp. quarterly revenues are --, which are smaller than ProMIS Neurosciences, Inc. quarterly revenues of --. Lexaria Bioscience Corp.'s net income of -$1.6M is higher than ProMIS Neurosciences, Inc.'s net income of -$11.6M. Notably, Lexaria Bioscience Corp.'s price-to-earnings ratio is -- while ProMIS Neurosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience Corp. is 23.44x versus -- for ProMIS Neurosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEXXLexaria Bioscience Corp.23.44x -- -- -$1.6M PMNProMIS Neurosciences, Inc.-- -- -- -$11.6M
-
Which has Higher Returns LEXX or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of -2178.51% compared to Lexaria Bioscience Corp.'s net margin of -867.29%. Lexaria Bioscience Corp.'s return on equity of -189.86% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.
Company Gross Margin Earnings Per Share Invested Capital LEXXLexaria Bioscience Corp.91.15% -$0.07 $4.6M XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M -
What do Analysts Say About LEXX or XENE?
Lexaria Bioscience Corp. has a consensus price target of $4.50, signalling upside risk potential of 605.77%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.82 which suggests that it could grow by 30.55%. Given that Lexaria Bioscience Corp. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LEXXLexaria Bioscience Corp.1 0 0 XENEXenon Pharmaceuticals, Inc.17 0 0 -
Is LEXX or XENE More Risky?
Lexaria Bioscience Corp. has a beta of 0.562, which suggesting that the stock is 43.753% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 0.957, suggesting its less volatile than the S&P 500 by 4.276%.
-
Which is a Better Dividend Stock LEXX or XENE?
Lexaria Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience Corp. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEXX or XENE?
Lexaria Bioscience Corp. quarterly revenues are --, which are smaller than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Lexaria Bioscience Corp.'s net income of -$1.6M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Lexaria Bioscience Corp.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience Corp. is 23.44x versus 449.37x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEXXLexaria Bioscience Corp.23.44x -- -- -$1.6M XENEXenon Pharmaceuticals, Inc.449.37x -- -- -$90.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
